Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis.
PTH 1-34
clinical trial
man
nasal delivery
osteoporosis
pharmacokinetics
preclinical
sheep
teriparatide
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
07 Jun 2019
07 Jun 2019
Historique:
received:
30
04
2019
revised:
20
05
2019
accepted:
24
05
2019
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
epublish
Résumé
Nasal delivery of large peptides such as parathyroid 1-34 (PTH 1-34) can benefit from a permeation enhancer to promote absorption across the nasal mucosa into the bloodstream. Previously, we have published an encouraging bioavailability (78%), relative to subcutaneous injection in a small animal preclinical model, for a liquid nasal spray formulation containing the permeation enhancer polyethylene glycol (15)-hydroxystearate (Solutol
Identifiants
pubmed: 31181662
pii: pharmaceutics11060265
doi: 10.3390/pharmaceutics11060265
pmc: PMC6631119
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Engineering and Physical Sciences Research Council
ID : EP/K502364/1
Organisme : Technology Strategy Board
ID : 17223-124195
Organisme : Engineering and Physical Sciences Research Council
ID : EP/K503800/1
Références
Int J Pharm. 1999 Feb 1;178(1):55-65
pubmed: 10205625
Int J Pharm. 2001 Apr 17;217(1-2):183-91
pubmed: 11292554
Osteoporos Int. 2006 Oct;17(10):1532-8
pubmed: 16767525
Expert Opin Drug Deliv. 2006 Jul;3(4):529-39
pubmed: 16822227
Arthritis Rheum. 2006 Oct 15;55(5):729-35
pubmed: 17013870
Eur J Pharm Sci. 2007 Mar;30(3-4):295-302
pubmed: 17223022
Eur J Pharm Sci. 2007 May;31(1):25-31
pubmed: 17368006
JAMA. 2008 Jan 9;299(2):211-3
pubmed: 18182604
Int J Pharm. 2008 Jun 5;357(1-2):70-6
pubmed: 18329197
Br J Anaesth. 2008 Oct;101(4):511-7
pubmed: 18723517
Calcif Tissue Int. 2010 Dec;87(6):485-92
pubmed: 20953593
Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):154-61
pubmed: 21771277
Age Ageing. 2012 May;41(3):322-6
pubmed: 22083839
J Clin Endocrinol Metab. 2012 Feb;97(2):311-25
pubmed: 22238383
J Aerosol Med Pulm Drug Deliv. 2012 Oct;25(5):280-9
pubmed: 22251061
Bone. 2012 Apr;50(4):965-73
pubmed: 22289659
J Control Release. 2012 Jul 20;161(2):254-63
pubmed: 22300620
Pharm Res. 2012 Sep;29(9):2543-54
pubmed: 22638869
J Control Release. 2012 Aug 20;162(1):194-200
pubmed: 22709592
Sci Transl Med. 2012 Sep 12;4(151):151ps15
pubmed: 22972841
Bone. 2013 Mar;53(1):160-6
pubmed: 23234813
Drug Deliv Transl Res. 2013 Feb;3(1):42-62
pubmed: 23316447
Pharm Res. 2015 Feb;32(2):516-27
pubmed: 25190006
J Clin Endocrinol Metab. 2015 Nov;100(11):4364-71
pubmed: 26425883
Osteoporos Int. 2016 Sep;27(9):2855-2865
pubmed: 27172935
Kidney Blood Press Res. 2016;41(5):507-518
pubmed: 27487342
Osteoporos Int. 2017 Apr;28(4):1355-1363
pubmed: 28058444
Int J Pharm. 2018 Jan 15;535(1-2):113-119
pubmed: 29038066
BMJ Open. 2018 Apr 12;8(4):e018898
pubmed: 29654006
Int J Pharm. 2018 Dec 20;553(1-2):8-20
pubmed: 30316796
Osteoporos Int. 2019 Mar;30(3):675-683
pubmed: 30357438
J Drug Target. 1996;3(6):427-42
pubmed: 8863136
Acta Anaesthesiol Scand. 1997 Feb;41(2):309-12
pubmed: 9062618